NiTech® reactors and crystallisers are perfect for the pharma/fine chemicals sector.
The technology is well aligned with emerging needs for lower cost, higher quality manufacturing processes that reduce carbon footprint. NiTech’s technology supports the major changes taking place in the sector’s business model as a result of:
- The escalating costs of developing new ‘blockbuster’ drugs (those with sales >$1bn) and the increasing failure rate of promising new compounds at a late stage in development.
- Intensifying competition from generic drugs, which dramatically reduce the potential for legacy earnings once patents have expired.
- Increasing demands from regulators for a ‘Quality by Design’ approach that provides scientific evidence of properly controlled manufacturing processes being in place, rather than empirical evidence after production.